Sumitomo Pharma: long-term performance & turning pointsSales (revenue) and profit-margin ratio
Sales (¥ bn)Net margin (%)
1897A venture pooled in Doshomachi
Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports
189721 Doshomachi drug merchants found Osaka Seiyaku with ¥100,000
1898Buys Dainippon Seiyaku of Tokyo and takes its name
1903Japan’s first anhydrous alcohol
1927Ephedrine hydrochloride launched as an asthma drug
Sumitomo Pharma began in May 1897 as a subscription. Twenty-one leading drug merchants of Doshomachi, the Osaka street where wholesalers of medicine had clustered since the Edo period, put up ¥100,000 between them and founded Osaka Seiyaku. Japanese-made medicines of the day were undercut by imports and by cheap, unreliable domestic imitations; the answer was a factory, and no single merchant house could carry that investment alone. A year later the company built its plant at Ebie, outside Osaka, bought the Tokyo firm Dainippon Seiyaku — a state-subsidised venture of 1883 and the first pharmaceutical company in Japan — and took its name.
The origin mattered more than the products. A company assembled by twenty-one subscribers had no founding family to protect and no doctrine of independence to defend; what it had instead was a habit of combining with others to make up for what it could not do alone. That habit runs through everything that follows.
The early line was galenicals — tinctures and syrups. In 1903 the company added alcohol and became the first in Japan to make anhydrous alcohol, whose quality carried it through the slump after the Russo-Japanese War. It absorbed the Osaka Drug Testing company in 1908, becoming the only private laboratory licensed to test and repackage medicines and hygiene goods; began narcotics manufacture in 1917 as a designated buyer of state opium; and in 1927 launched ephedrine hydrochloride, discovered by Nagai Nagayoshi, as an asthma treatment. Branches in Mukden and a plant in Hsinking followed the army into the continent, and the war destroyed them.
1968Suzuka plant opens (1971: Osaka research centre)
1993Dainippon Pharmaceutical U.S.A. established in California
2003The founding Osaka plant closes after 106 years
Rebuilding meant retrenchment — a 1950 rationalisation that cut staff and closed plants — and then partnership. From 1952 the company licensed from foreign firms: the ulcer drug Banthine and the antihypertensive Ecolid came from G. D. Searle, and a joint venture with Abbott produced Dainabot Radioisotope Laboratories and a business in radiopharmaceuticals. It listed on the Osaka and Tokyo exchanges in 1949 and was assigned to the First Section of the Tokyo Stock Exchange in 1961; the Suzuka plant (1968) and the Osaka research centre (1971) gave it a two-site structure for making and discovering synthetic drugs.
That structure worked for eight decades of independence, but it was sized for a mid-tier firm, and by the 1990s the research bill for a new drug had outgrown the position. Takeda, Daiichi Sankyo and Astellas were spending over ¥100bn a year on R&D; Dainippon was not. In January 1993 it opened Dainippon Pharmaceutical U.S.A. in California — a single small entity, with overseas sales still in single digits as a share of the total, but a window of its own onto American licensing and clinical development.
The end came as a subtraction. In April 2003 the Osaka plant — the company’s original works, running since 1898 — was closed and production consolidated at Suzuka. For the year to March 2004 consolidated sales were ¥170.8bn and recurring profit ¥10.1bn. At that scale a company cannot keep a new-drug pipeline turning indefinitely, and management said so; the closure of the founding site and the decision to merge are two readings of the same arithmetic.
2005Merges with Sumitomo Pharmaceuticals as Dainippon Sumitomo Pharma
2009Buys Sepracor Inc. for about $2.6bn
2010Latuda approved and launched in the United States
2017Record operating profit of ¥88.1bn
2019Takes control of Sumitovant Biopharma for about $3bn
In October 2005 Dainippon Pharmaceutical merged with Sumitomo Pharmaceuticals of the Sumitomo Chemical group to form Dainippon Sumitomo Pharma, taking on the Ibaraki, Ehime and Oita plants, the Osaka research site and Sumitomo Pharmaceuticals (Suzhou) in China. Miyatake Kenjiro became its first president, succeeded by Tada Masayo in 2008. The logic was two-sided: Dainippon’s synthetic-chemistry portfolio was complemented by Sumitomo’s promising candidates in central nervous system and cardiovascular disease, and the group’s balance sheet would fund an American push that neither could have afforded alone. Sales reached ¥245.8bn in FY05 and ¥264.0bn by FY07.
One of the inherited candidates decided the next fifteen years. Lurasidone — later Latuda — an atypical antipsychotic, showed strong Phase III results in the United States, and how to sell it there became the central question of the merged company. In October 2009 Dainippon Sumitomo bought Sepracor Inc. for about $2.6bn, later reorganised as Sunovion, acquiring an American psychiatric sales organisation outright. Latuda was approved and launched in the US in 2010; FY10 sales jumped to ¥379.5bn, roughly 1.5 times the level at the merger only four years earlier.
Success then justified more of the same. Boston Biomedical (2012), Cynapsus of Canada with the Parkinson’s rescue drug Kynmobi (2016) and Tolero Pharmaceuticals (2017) were bought in oncology and neurology; FY17 operating profit hit a record ¥88.1bn. In December 2019 the company put about $3bn into taking control of Sumitovant Biopharma from Roivant Sciences, acquiring Orgovyx, Myfembree and Gemtesa in one package as Latuda’s designated successors. FY21 sales of ¥560bn were more than double the merger-year figure — and the loss of US exclusivity on Latuda was one year away.
2022Renamed Sumitomo Pharma; ¥54.4bn impairment on Kynmobi
2023Net loss of about ¥315bn; Kimura Toru becomes president
2024Net income of ¥23.6bn — a ¥338.6bn swing
2025“Reboot 2027”: Asia sold; focus on the US and Japan
In April 2022 the company renamed itself Sumitomo Pharma and moved to the TSE Prime Market; president Nomura Hiroshi framed the new name around discovery plus new fields such as robotics and regenerative medicine. Six months later the second-quarter results carried a ¥54.4bn impairment on Kynmobi, the 2016 acquisition, and a quarterly operating loss of ¥28.9bn. Nomura conceded the original judgement had been wrong — the company had targeted peak sales of $500m and landed far below — blaming an overestimate of the addressable Parkinson’s population and oral safety problems with the sublingual film. The write-down was less an isolated event than the moment the market stopped taking the North American acquisition plans at face value.
FY23 settled the account: on revenue of ¥314.6bn, a net loss of roughly ¥315bn, as the plans for Orgovyx, Myfembree and Gemtesa collapsed and the Sumitovant goodwill and intangibles were written off almost in a single stroke. Nomura’s departure and the promotion of vice-president Kimura Toru were announced the same day — an unusual joint appearance that signalled Sumitomo Chemical taking the pharmaceutical business back in hand. The restructuring matched the write-off in scale: North American headcount cut from 2,200 to 1,200, $500m of dollar-denominated SG&A removed, ulotaront handed to Otsuka, the pipeline trimmed from 22 projects to 17, and seven US entities folded into Sumitomo Pharma America. Eighteen years of expansion were compressed in one.
FY24 reversed it: revenue ¥398.8bn, core operating profit ¥43.2bn and net income ¥23.6bn — a ¥338.6bn swing from the prior year, as Orgovyx and Gemtesa outran the assumptions the impairment had been based on. In May 2025 the Reboot 2027 plan drew the new perimeter: the China and Asia businesses sold to Marubeni Global Pharma in two tranches for $481.1M (¥72bn) in total, the frontier businesses to Sawai Group Holdings, and resources concentrated on the United States and Japan, the two markets where new drugs are sold. The one small American entity opened in 1993 had become the company; almost everything else was let go.
A company started with ¥100,000 pooled by twenty-one drug merchants chose, 106 years later, not to buy another drug candidate but to acquire a parent. Thin in proprietary compounds, able to run only one clinical development programme abroad, outsold three to one on a drug it had co-developed — the weakness visible in 2004 was not the kind that a single injection of capital removes. The calculation, it appears, was that unless the earning power itself moved under different capital, the company’s turn at the next new drug would never come. This was a merger designed from the admission that it could not win alone.
That the decision looks so unencumbered may be because Dainippon Pharmaceutical never had a single master. A company born of a subscription had no founding family to protect and no non-negotiable doctrine of independence — and, by the same token, little resistance to handing over a majority of its shares. When people involved at the time called Sumitomo Chemical’s promise to hold that majority for ten years a “guarantee of identity,” it was because they knew which side of the arrangement they were now on. The strength the merger created went four years later into a $2.6bn acquisition, and beyond that the company would take on a different kind of weight.
At the heart of this decision is a mid-tier maker with one promising drug choosing to sell it out in the United States itself rather than entrust it to a major’s distribution. Buying an entire company for its field force was a coherent route to maximising the value of a single compound, lurasidone. Coming at the same moment as Takeda’s purchase of Millennium and Daiichi Sankyo’s of Ranbaxy, this deal took a different road to scale from the top tier — expansion staked on one product.
But securing the channel first and pushing a single drug through it was inseparable from dependence on that drug. While Latuda’s success retrospectively justified one North American acquisition after another, the concentration of earnings in one product quietly deepened. As the expiry of US exclusivity approached, that dependence rose as the next heavy problem. The 2009 decision to own a channel in America was the opening move of expansion and, at the same time, the first sign of the concentration risk that came later.
When the company paid $2.6bn for Sepracor, what it bought was an American sales network. When it paid about $3bn for the Roivant deal, what it bought was a mechanism for selecting and advancing drug candidates, and the twenty-five-plus programmes hanging from it. The shift over ten years from product to probability was driven, it seems, by both the experience of having hit once with a single agent in Latuda and the fixed date — February 2023 — on which that agent would disappear. It was a decision to buy with money what cannot be bought with time.
Buying probability, however, does not guarantee a batting average. All three acquired products reached the market, yet the business plans were missed, and ¥133.5bn of Myfembree patent rights were converted into an impairment. Given that Orgovyx landed at 136% of the initial forecast in the year to March 2025, what was wrong may have been less the strength of the products than the way the revenue plans built on them were set. When Kimura Toru chose his words carefully — that whether the alliance succeeded “is something we will verify” — it showed that even the people inside it cannot yet draw that line.
How much loss you can afford to take decides the strategy
An impairment of $1.3B (¥181bn) is more than half that year’s revenue of ¥314.6bn. What the company chose was to take that loss in one year rather than spread it over several. Spread out, it would have meant losses every period and continuing breaches of financial covenants. Taken at once, the following year’s income statement is unburdened — and the numbers for the year to March 2025, net income of ¥23.6bn and an improvement of ¥338.6bn, show exactly how that works. It is a case where an accounting treatment created the entrance to a turnaround.
What decided how much loss could be taken, though, was not the company. Having breached its covenants at year-end, Sumitomo Pharma kept the benefit of term through debt guarantees from its parent, Sumitomo Chemical. The judgement to take the write-down in one go presupposed the capital standing behind it. The counterparty to which Dainippon Pharmaceutical handed a majority of its shares in 2005 had, eighteen years later, become the party keeping the company alive. What it meant for a firm that walked 106 years as an independent mid-tier to acquire a parent showed more plainly in these two years of folding back than in all the years of expansion.
Each heading links to the full Japanese analysis — background, decision and outcome, with sources.
This is a condensed English edition. The full, source-by-source history — with the detailed narrative, financial tables, shareholders and executives — is maintained in Japanese: 日本語版（詳細）— Sumitomo Pharma full history in Japanese →
This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
Company names, logos and other marks belong to their respective owners.
Data API
Sumitomo Pharma’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.